RSS feed Get our RSS feed

News by Topic

BizReport : White Papers : Biotechnology & Pharmaceuticals

Paying Physicians to Presribe Generic Drugs and Follow-On Biologics in the United States

Summary Points:

  • Spending on brand-name prescription medications, particularly brand-name biologic drugs, continues to increase.
  • Considerable savings and improvements in medication adherence are possible from greater use of more affordable generic drugs and imminently available follow-on biologics.
  • Strategies to promote greater prescribing of generic drugs and follow-on biologics include traditional information-supplying programs such as formulary decision support and academic detailing and more novel financial incentives.
  • While private insurers, qualified health plans, and employers may legally offer physicians financial incentives to prescribe generic drugs and follow-on biologics, marginally greater risks and a developing evidence base militates against physician payment for therapeutic or noninterchangeable follow-on biologic substitution, and—at this time— for bioequivalent substitution of narrow therapeutic index (NTI) drugs or interchangeable follow-on biologic substitution.
  • Implementation of the various physician-centered strategies to promote greater prescribing of generic drug and follow-on biologics must be accompanied by comparative cost-utility studies assessing patient health outcomes.

Click here to request your free White Paper!




Copyright © 1999- BizReport. All rights reserved.
Republication or redistribution of BizReport content is expressly prohibited without the prior written consent.
BizReport shall not be liable for any errors in the content, or for any actions taken in reliance thereon.